Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Blood|July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaDavid S Siegel, Thomas Martin, Michael Wang, et al.
Future Oncology (London, England)|May 22, 2023
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myelomaThierry Facon, Shaji K Kumar, Torben Plesner, et al.
Blood|January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyPaul G Richardson, David S Siegel, Ravi Vij, et al.
Ejhaem|July 18, 2022
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myelomaCristina Gasparetto, Suzanne Lentzsch, Gary Schiller, et al.
European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Plos Genetics|October 7, 2025
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myelomaIsabelle Bergiers, Murat Cem Köse, Sheri Skerget, et al.
Transplantation and Cellular Therapy|June 9, 2021
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple MyelomaSarah A Holstein, Nizar Bahlis, P Leif Bergsagel, et al.
Leukemia|January 15, 2025
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA studyPhilippe Moreau, Thierry Facon, Saad Z Usmani, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 5, 2023
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 StudyThomas G Martin, Philippe Moreau, Saad Z Usmani, et al.
Leukemia|February 27, 2025
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomesThierry Facon, Philippe Moreau, Katja Weisel, et al.
Pageof 6